USOR 25065 - STAR Beamion LUNG3 study of zongertinib with patients with NSCLC

A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Disease Types: Colorectal, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago, Niles